FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated PatientsSrđan Verstovšek, Jean‐Jacques Kiladjian, Jay Patel et al.|Blood|2022Cited by 14
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrđan Verstovšek, Jason Gotlib, Stephen T. Oh et al.|NEJM Evidence|2025Cited by 7